Health Care • Biotechnology: Pharmaceutical Preparations
$45.37 ▲ +0.12
(+0.27%)
MKT CAP: $7.61B • VOL: 1.43M
52W L $27 52W H $56
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$38
MEDIAN
$51
MEAN
$52
HIGH
$62
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE ALKS TAPE
ALKS // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $54.90 | $52.18 | 2025-02-14 | $41.29 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $57.17 | $53.54 | 2025-02-06 | $42.65 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $51.72 | $49.91 | 2025-01-29 | $43.56 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $46.28 | — | 2025-01-17 | $44.46 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $39.93 | $43.10 | 2025-01-09 | $40.38 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $53.99 | $47.18 | 2024-12-18 | $39.47 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $44.01 | $45.82 | 2024-12-04 | $42.19 | -4.3% | 48% | C |